RG 210179
Alternative Names: RG-210179Latest Information Update: 22 Jan 2024
At a glance
- Originator Apoglyx
- Class Anti-inflammatories; Small molecules
- Mechanism of Action AQP9 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatitis
Most Recent Events
- 19 Dec 2023 Preclinical trials in Pancreatitis in Sweden (unspecified route), before 2023 (Apoglyx website, December 2023)
- 19 Dec 2023 Apoglyx plans clinical trial for Pancreatitis (Apoglyx website, December 2023)